ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM)

Li, Fei; Zhang, Yifan; Lin, Zhoujun; Yan, Lizhong; Liu, Qiao; Li, Yin; Pei, Xiaolin; Feng, Ya; Han, Xiao; Yang, Juan; Zheng, Fangxu; Li, Tianjiao; Zhang, Yupeng; Fu, Zhenkun; Shao, Di*; Yu, Jane*; Li, Chenggang*南开大学; 哈尔滨医科大学; 重庆大学
Cell Death & Disease2022-12-21DOI: 10.1038/s41419-022-05511-3
2被引7阅读
引用收藏
分享

摘要

Lymphangioleiomyomatosis (LAM), a progressive pulmonary disease exclusively affecting females, is caused by defects or mutations in the coding gene tuberous sclerosis complex 1 (TSC1) or TSC2, causing the mammalian target of rapamycin complex 1 (mTORC1) activation and autophagy inhibition. Clinically, rapamycin shows limited cytocidal effects, and LAM recurs after drug withdrawal. In this study, we demonstrated that TSC2 negatively regulated the sphingolipid metabolism pathway and the expressions of sphingosine kinase 1 (SPHK1) and sphingosine-1-phosphate receptor 3 (S1PR3) were significantly elevated in LAM patient-derived TSC2-deficient cells compared to TSC2-addback cells, insensitive to rapamycin treatment and estrogen stimulation. Knockdown of SPHK1 showed reduced viability, migration and invasion in TSC2-deficient cells. Selective SPHK1 antagonist PF543 potently suppressed the viability of TSC2-deficient cells and induced autophagy-mediated cell death. Meanwhile, the cognate receptor S1PR3 was identified to mediating the tumorigenic effects of sphingosine-1-phosphate (S1P). Treatment with TY52156, a selective antagonist for S1PR3, or genetic silencing using S1PR3-siRNA suppressed the viability of TSC2-deficient cells. Both SPHK1 and S1PR3 inhibitors markedly exhibited antitumor effect in a xenograft model of TSC2-null cells, restored autophagy level, and triggered cell death. Together, we identified novel rapamycin-insensitive sphingosine metabolic signatures in TSC2-null LAM cells. Therapeutic targeting of aberrant SPHK1/S1P/S1PR3 signaling may have potent therapeutic benefit for patients with TSC/LAM or other hyperactive mTOR neoplasms with autophagy inhibition.

学科与关键词

关键词
TUBEROUS SCLEROSIS COMPLEXSPHINGOSINE 1-PHOSPHATESPHINGOSINE-1-PHOSPHATELYMPHANGIOLEIOMYOMATOSISTUMORIGENESISRAPAMYCINESTRADIOLKINASEMODEL
相关
加载中…
  • Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer
    Lin, Zhoujun; Li, Yin; Han, Xiao; Fu, Zhenkun; Tian, Zhenhuan*; Li, Chenggang*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23(21): 12741.被引 3
  • Sphingosine Kinase 1 Regulates the Akt/FOXO3a/Bim Pathway and Contributes to Apoptosis Resistance in Glioma Cells
    Guan Hongyu*; Song Libing; Cai Junchao; Huang Yongbo; Wu Jueheng; Yuan Jie; Li Jun; Li MengfengPLoS ONE, 2011, 6(5): e19946.被引 39
  • Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-kappa B Pathway in Human Non-Small Cell Lung Cancer
    Song Libing*; Xiong Huaping; Li Jun; Liao Wenting; Wang Lan; Wu Jueheng; Li MengfengClinical Cancer Research, 2011, 17(7): 1839-1849.被引 62
查看全部 →

发表信息

论文状态
公开发表
期刊
Cell Death & Disease
发表日期
2022-12-21
卷期
第 13 卷, 第 12 期
页码
1065
DOI
10.1038/s41419-022-05511-3
语言
ENGLISH
成果收录
SCIE
资助标注
Chongqing Science and Technology Bureau of China [cstc2019jcyj-msxm1819]; National Natural Science Foundation of China [81901427]; "The Fundamental Research Funds for the CentralUniversities", Nankai University [ZB19100128]; Tianjin Natural Science Foundation [18JCYBJC40700]; Open fund of State Key Laboratory of Pharmaceutical Biotechnology, Nan-Jing University [KF-GN-201701]

作者

  • L

    Li, Fei (第一作者)

    nankai univ

  • Z

    Zhang, Yifan

    nankai univ

查看全部 17 位作者收起作者
  • L

    Lin, Zhoujun

    nankai univ

  • Y

    Yan, Lizhong

    nankai univ

  • L

    Liu, Qiao

    nankai univ

  • L

    Li, Yin

    nankai univ

  • P

    Pei, Xiaolin

    nankai univ

  • F

    Feng, Ya

    nankai univ

  • H

    Han, Xiao

    nankai univ

  • Y

    Yang, Juan

    nankai univ

  • Z

    Zheng, Fangxu

    nankai univ

  • L

    Li, Tianjiao

    nankai univ

  • Z

    Zhang, Yupeng

    nankai univ

  • F

    Fu, Zhenkun

    nankai univ · harbin med univ

  • S

    Shao, Di (通讯)

    chongqing emergency med ctr · chongqing univ

  • Y

    Yu, Jane (通讯)

  • L

    Li, Chenggang (通讯)

    nankai univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417